Although systemic agents for the treatment of metastatic renal cell carcinoma (mRCC) have improved survival, remission and cure for mRCC remains rare with systemic therapy alone. However, there is a body of observational evidence supporting a survival benefit in mRCC among patients who undergo complete surgical consolidation including resection of the primary tumor and all […]
Clinically Meaningful Response and Sustained Durability Underscore Potential for UGN-102 to Become a Non-Surgical Primary Therapeutic Treatment for Patients with Highly Recurrent LG IR-NMIBC 65% Complete Response (CR) Rate at Three Months 61% of Patients Remain in CR at 12 Months Data Supports Ongoing Phase 3 Development of UGN-102 in LG IR-NMIBC as an Alternative […]
Christopher Wallis: Hello, and thank you for joining us for a UroToday discussion, of NCCN Clinical Practice Guidelines in Oncology. Today we’re focusing on the prostate cancer guidelines of February 2021, with a focus on nuances in advanced prostate cancer, including neuroendocrine disease, bone and visceral metastases, and treatment sequencing. I’m Chris Wallis, an Assistant […]
Zachary Klaassen: Hello, and thank you for joining us for this NCCN Clinical Practice Guideline in Oncology Prostate Cancer discussion. Today, we’ll be discussing the epidemiology, initial diagnosis, and life expectancy with prostate cancer. My name is Zachary Klaassen. I’m an Assistant Professor at the Division of Urology at the Medical College of Georgia. And […]
The amendments to the “Strengthening Europe in the fight against cancer – towards a comprehensive and coordinated strategy” report from the European Parliament Special Committee on Beating Cancer (BECA Committee) have come in. We are delighted to see that our collective advocacy with European cancer patients and researchers has led to strong messages on prostate cancer. Over […]
Background and objectives: Despite a generally good prognosis, testicular cancer can be a life-altering event. We explored perceived positive and negative life changes after testicular cancer in terms of frequency, demographic and disease-related predictors, and associations with depression and anxiety.
Nivolumab showed an overall survival (OS) benefit in pretreated metastatic renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC remains to be defined. Our aim was to evaluate the efficacy and safety of SBRT in combination with nivolumab in second- and third-line mRCC patients.
While immune checkpoint inhibitors (ICI) can lead to sustained responses in metastatic renal cell carcinoma (mRCC), the optimal duration of therapy remains unknown. We aimed to examine treatment-free survival (TFS) in objective responders who discontinued ICI and to explore factors that may impact objective response rate (ORR) and TFS.
Financial toxicity is an underappreciated component of cancer survivorship. Treatment-specific out-of-pocket costs for patients undergoing localized prostate cancer treatment have not, to date, been described and may influence patient’s decision making.
Dairy products have been indicated as a risk factor for prostate cancer. However, only a few epidemiological studies have reported dairy products as being a risk factor for prostate cancer in Japan, reporting contradictory results.
